Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

• DOI: 10.1200/jco.2017.77.0446
• Publication Date: 2018-01-30T13:00:34Z
• Authors: John Heymach; Lada Krilov; Anthony Alberg; Nancy Baxter; Susan Marina Chang; Ryan B. Corcoran; William Dale; Angela DeMichele; Catherine S. Magi...; Robert Dreicer; Andrew S. Epstein; Maura L. Gillison; David L. Graham; Joshua Jones; Andrew H. Ko; Ana Maria Lopez; Robert G. Maki; Carlos Rodriguez-...; Richard L. Schilsky; Mario Sznol; Shannon Neville W...; Harold Burstein
• Keywords: Cancer Immunotherapy; Clinical Oncology

A MESSAGE FROM ASCO'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, progress we have chronicled is remarkable, and this year no different. The featured ASCO's Clinical Cancer Advances 2018 underscores impressive gains our understanding ability to tailor treatments tumors' genetic makeup. Advance Year, adoptive cell immunotherapy, allows clinicians genetically reprogram patients' own immune cells find attack throughout body. Chimeric antigen receptor (CAR) T-cell therapy-a type immunotherapy-has led remarkable results young patients with acute lymphoblastic leukemia (ALL) adults lymphoma multiple myeloma. Researchers are also exploring approach other types cancer. This advance would not be possible without robust federal investment research. clinical trial CAR therapy children ALL was funded, part, by grants from National Institute (NCI), researchers at NCI Center for Research were These discoveries follow decades prior immunology biology, much which supported dollars. In fact, many advances that highlighted made thanks nation's support biomedical Funding US Institutes Health helps pursue critical patient care questions addresses vital, unmet needs private industry has little incentive take on. Federally generates innovations fuel development availability new improved patients. We need sustained accelerate discovery next generation treatments. Another major trend year's precision medicine approaches treat Although offers promise people their families, only as good make these available all My presidential theme, "Delivering Discoveries: Expanding Reach Precision Medicine," focuses tackling formidable challenge so targeted therapies accessible anyone who faces a diagnosis. By improving access high-quality care, harnessing big data outcomes across globe, pursuing innovative trials, am optimistic will speed delivery promising more Sincerely, Bruce E. Johnson, FASCO President, 2017 2018.